Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Tirzepatide.

Research draft

Tirzepatide is a dual GIP and GLP-1 receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Tirzepatide is a dual GIP and GLP-1 receptor agonist.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It influences glucose-dependent insulin secretion, appetite and energy intake.

Human research

Large randomised trials support diabetes and weight-management benefits in defined populations. Other outcomes depend on the specific product label.

Preclinical & other research

Receptor and metabolic models support dual-incretin action.

Safety & unknowns

Gastrointestinal effects are common; pancreatic, gallbladder, dehydration and contraindication warnings matter.

Regulatory status

Mounjaro and Zepbound are approved US products with distinct labelled uses; online preparations are not automatically equivalent.

Reported use & evidence

Research profile draft

The supplied Tirzepatide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds